This company has been marked as potentially delisted and may not be actively trading. ERYTECH Pharma (ERYP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ERYP vs. PRME, IKT, PLX, IZTC, ACHL, ZIVO, BLUE, CRTX, CYTH, and FNCHShould you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Prime Medicine (PRME), Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), Invizyne Technologies (IZTC), Achilles Therapeutics (ACHL), ZIVO Bioscience (ZIVO), bluebird bio (BLUE), Cortexyme (CRTX), Cyclo Therapeutics (CYTH), and Finch Therapeutics Group (FNCH). These companies are all part of the "medical" sector. ERYTECH Pharma vs. Its Competitors Prime Medicine Inhibikase Therapeutics Protalix BioTherapeutics Invizyne Technologies Achilles Therapeutics ZIVO Bioscience bluebird bio Cortexyme Cyclo Therapeutics Finch Therapeutics Group Prime Medicine (NYSE:PRME) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends. Do analysts prefer PRME or ERYP? Prime Medicine currently has a consensus price target of $10.08, indicating a potential upside of 219.09%. Given Prime Medicine's stronger consensus rating and higher possible upside, equities research analysts plainly believe Prime Medicine is more favorable than ERYTECH Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75ERYTECH Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer PRME or ERYP? In the previous week, Prime Medicine had 3 more articles in the media than ERYTECH Pharma. MarketBeat recorded 3 mentions for Prime Medicine and 0 mentions for ERYTECH Pharma. Prime Medicine's average media sentiment score of 0.97 beat ERYTECH Pharma's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media. Company Overall Sentiment Prime Medicine Positive ERYTECH Pharma Neutral Which has higher earnings and valuation, PRME or ERYP? ERYTECH Pharma has higher revenue and earnings than Prime Medicine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$3.85M107.88-$198.13M-$1.61-1.96ERYTECH Pharma$32.66M3.24-$240KN/AN/A Is PRME or ERYP more profitable? ERYTECH Pharma's return on equity of 0.00% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% ERYTECH Pharma N/A N/A N/A Do insiders & institutionals believe in PRME or ERYP? 70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 1.1% of ERYTECH Pharma shares are held by institutional investors. 22.9% of Prime Medicine shares are held by company insiders. Comparatively, 1.9% of ERYTECH Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, PRME or ERYP? Prime Medicine has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, ERYTECH Pharma has a beta of 2.69, meaning that its stock price is 169% more volatile than the S&P 500. SummaryPrime Medicine beats ERYTECH Pharma on 9 of the 14 factors compared between the two stocks. Get ERYTECH Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERYP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERYP vs. The Competition Export to ExcelMetricERYTECH PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.77M$205.22M$5.56B$9.04BDividend YieldN/AN/A5.24%4.01%P/E RatioN/AN/A27.6120.24Price / Sales3.24223.65417.30118.22Price / CashN/A22.4436.8958.10Price / Book3.885.618.035.67Net Income-$240K-$96.61M$3.18B$249.21M ERYTECH Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERYPERYTECH PharmaN/A$3.10flatN/AN/A$105.77M$32.66M0.0049PRMEPrime Medicine3.7573 of 5 stars$2.46+13.9%$10.08+309.9%-40.8%$322.98M$3.85M-1.20234Gap UpHigh Trading VolumeIKTInhibikase Therapeutics1.3635 of 5 stars$1.66flat$6.50+291.6%+64.3%$123.41M$260K-0.626News CoverageGap UpPLXProtalix BioTherapeutics2.9137 of 5 stars$1.53+13.3%$15.00+880.4%+48.6%$121.80M$59.76M-11.77200Gap UpIZTCInvizyne TechnologiesN/A$10.50+14.8%N/AN/A$65.65MN/A0.0029News CoverageGap UpACHLAchilles TherapeuticsN/A$1.48flatN/AN/A$60.83MN/A-0.90250ZIVOZIVO BioscienceN/A$14.91+4.9%N/A+69.8%$56.85M$15.85K-3.0610Gap UpBLUEbluebird bio2.1243 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520News CoverageCRTXCortexymeN/A$1.32+1.5%N/A+129.8%$39.80MN/A-0.4455CYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809FNCHFinch Therapeutics Group1.0633 of 5 stars$13.00-0.1%N/A+921.5%$20.88M$110K-1.47190News Coverage Related Companies and Tools Related Companies PRME Alternatives IKT Alternatives PLX Alternatives IZTC Alternatives ACHL Alternatives ZIVO Alternatives BLUE Alternatives CRTX Alternatives CYTH Alternatives FNCH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERYP) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ERYTECH Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share ERYTECH Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
